Citius Pharmaceuticals (NASDAQ:CTXR) Earns Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR) in a report released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $9.00 target price on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Citius Pharmaceuticals in a report on Tuesday, November 12th.

Citius Pharmaceuticals Trading Down 15.1 %

Shares of CTXR opened at $3.71 on Tuesday. Citius Pharmaceuticals has a twelve month low of $2.44 and a twelve month high of $26.75. The firm has a market capitalization of $28.67 million, a P/E ratio of -0.62 and a beta of 1.30. The firm’s 50-day moving average is $4.78 and its two-hundred day moving average is $11.44.

Institutional Investors Weigh In On Citius Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Armistice Capital LLC acquired a new position in Citius Pharmaceuticals during the second quarter worth about $5,928,000. Geode Capital Management LLC increased its stake in shares of Citius Pharmaceuticals by 14.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,878,953 shares of the company’s stock worth $941,000 after purchasing an additional 232,656 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Citius Pharmaceuticals during the 2nd quarter worth approximately $118,000. Cubist Systematic Strategies LLC purchased a new stake in Citius Pharmaceuticals in the 2nd quarter valued at approximately $69,000. Finally, Virtu Financial LLC acquired a new stake in Citius Pharmaceuticals during the 3rd quarter valued at $50,000. 16.88% of the stock is owned by institutional investors and hedge funds.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.